APPLICATION OF A SYSTEM-ANALYSIS APPROACH TO POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF NICARDIPINE HYDROCHLORIDE IN HEALTHY-MALES

被引:6
作者
MODI, NB
VENGPEDERSEN, P
GRAHAM, DJ
DOW, RJ
机构
[1] UNIV IOWA,COLL PHARM,IOWA CITY,IA 52242
[2] SYNTEX RES CTR,EDINBURGH,SCOTLAND
关键词
D O I
10.1002/jps.2600820707
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Nicardipine hydrochloride, a dihydropyridine calcium channel blocker, possesses antihypertensive and arterial vasodilator properties. A system analysis approach, which makes fewer structural assumptions than compartmental methods, is presented for determining the pharmacokinetics and pharmacodynamics of nicardipine hydrochloride in healthy males following a discontinuous infusion at four dose levels. The results indicate that the average total body clearance of nicardipine is 0.920 L/h/kg and the volume of distribution is 0.275 L/kg. Nicardipine hydrochloride has a mean residence time in the body of 1.27 h, of which 0.324 h were spent in the systemic circulation and the remainder in the periphery. The determined pharmacokinetic model was linked to a pharmacodynamic model that allowed the change in the mean arterial blood pressure and heart rate to be described and predicted. A population pharmacokinetic-pharmacodynamic model was derived and the predictive power of the proposed model was assessed with a cross-validation technique that employs a relative predictive quotient for comparing the predictions to the fitted model. The results indicate that the proposed model describes the pharmacodynamics of nicardipine in healthy males and has good predictive ability when tested with a cross-validation procedure.
引用
收藏
页码:705 / 713
页数:9
相关论文
共 34 条
  • [1] Akaike H., 1976, MATH SCI, V14, P5
  • [2] 1ST-STEP TREATMENT OF MILD TO MODERATE UNCOMPLICATED ESSENTIAL-HYPERTENSION BY A NEW CALCIUM-ANTAGONIST - NICARDIPINE
    BELLET, M
    LORIA, Y
    LALLEMAND, A
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1985, 7 (06) : 1149 - 1153
  • [3] SIMULTANEOUS MODELING OF THE PHARMACOKINETICS AND METHEMOGLOBIN PHARMACODYNAMICS OF AN 8-AMINOQUINOLINE CANDIDATE ANTIMALARIAL (WR 238605)
    BRUECKNER, RP
    FLECKENSTEIN, L
    [J]. PHARMACEUTICAL RESEARCH, 1991, 8 (12) : 1505 - 1510
  • [4] NONINVASIVE ASSESSMENT OF THE HEMODYNAMIC-EFFECTS OF NICARDIPINE IN NORMOTENSIVE SUBJECTS
    CAMPBELL, BC
    KELMAN, AW
    HILLIS, WS
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 20 : S55 - S61
  • [5] ACUTE PHARMACOKINETIC AND HEMODYNAMIC-EFFECTS OF INTRAVENOUS BOLUS DOSING OF NICARDIPINE
    CHEUNG, DG
    GASSTER, JL
    NEUTEL, JM
    WEBER, MA
    [J]. AMERICAN HEART JOURNAL, 1990, 119 (02) : 438 - 442
  • [6] CLIFTON G, 1989, CLIN PHARMACOL THER, V45, P143
  • [7] CONRAD KA, 1989, CLIN PHARMACOL THER, V42, P113
  • [8] PHARMACOKINETICS, PHARMACODYNAMICS, AND MINIMUM EFFECTIVE CLINICAL DOSE OF INTRAVENOUS NICARDIPINE
    COOK, E
    CLIFTON, GG
    VARGAS, R
    BIENVENU, G
    WILLIAMS, R
    SAMBOL, N
    MCMAHON, G
    GRANDY, S
    LAI, CM
    QUON, C
    ANDERSON, CR
    TURLAPATY, P
    WALLIN, JD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (06) : 706 - 718
  • [9] LINEAR-SYSTEMS ANALYSIS IN PHARMACOKINETICS
    CUTLER, DJ
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1978, 6 (03): : 265 - 282
  • [10] NONCOMPARTMENTAL VERSUS COMPARTMENTAL MODELING IN CLINICAL PHARMACOKINETICS
    GILLESPIE, WR
    [J]. CLINICAL PHARMACOKINETICS, 1991, 20 (04) : 253 - 262